title: Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma.
abstract: This analysis reports on 72 patients with relapsed or refractory non-Hodgkin lymphoma who were treated with R-DHAP salvage chemotherapy regimen followed by high-dose chemotherapy and stem cell transplantation. The overall remission rate was 58.3%. Median time of follow-up was 28.7 months. Median progression-free survival was 29 months, estimated median overall survival was 37 months. Within a matched pair analysis these results were compared to a group that received DHAP salvage therapy without rituximab showing similar overall response rates and better estimated five-year overall survival of 59.2% versus 43.5%. R-DHAP therapy was shown to be effective and feasible with acceptable toxicity.
authors.affiliation: a Center for Integrated Oncology (CIO) , University Hospital Bonn , Bonn , Germany.
authors.forename: Nadine G D
authors.initials: NG
authors.lastname: Schirmbeck
authors.affiliation: b Departement Innere Medizin , Medizinische Onkologie und Hämatologie , Kantonsspital Graubünden, Chur , Switzerland.
authors.forename: Ulrich J M
authors.initials: UJ
authors.lastname: Mey
authors.affiliation: c Department of Hematology , Ancona University , Ancona , Italy.
authors.forename: Attilio
authors.initials: A
authors.lastname: Olivieri
authors.affiliation: d Internistische Onkologie , Johanniter Krankenhaus , Bonn , Germany.
authors.forename: Yon-Dschun
authors.initials: YD
authors.lastname: Ko
authors.affiliation: e Onkologisches Zentrum , St. Bernward Krankenhaus , Hildesheim , Germany.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Kaiser
authors.affiliation: f Medizinische Klinik I , GPR Klinikum Rüsselsheim , Rüsselsheim , Germany.
authors.forename: Dimitri
authors.initials: D
authors.lastname: Flieger
authors.affiliation: g Zentrumfür Innere Medizin (KrehlKlinik) , Innere Medizin V: Klinik für Hämatologie, Onkologie, Rheumatologie, Universitäts Klinikum Heidelberg , Heidelberg , Germany.
authors.forename: Mathias
authors.initials: M
authors.lastname: Witzens-Harig
authors.affiliation: a Center for Integrated Oncology (CIO) , University Hospital Bonn , Bonn , Germany.
authors.forename: Ingo G H
authors.initials: IG
authors.lastname: Schmidt-Wolf
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D019233:Retreatment; D000069283:Rituximab / Q000008:administration & dosage; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D003561:Cytarabine; D000069283:Rituximab; D003907:Dexamethasone; D002945:Cisplatin
keywords: Lymphomas; therapy; treatment; tumor immunology